Spotlight: Ketamine Harm Reduction
Prevention & Treatment in Ketamine Use Disorder - When a medicine becomes a poison
Spotlight: The effects of low-dose ketamine and (2R,6R)-Hydroxynorketamine on affective behaviors associated with protracted oxycodone withdrawal (Lehane, et al, 2025)
"These findings demonstrate the therapeutic potential of (2R,6R)-HNK and ketamine in alleviating affective symptoms of oxycodone withdrawal. "
Naltrexone in the Treatment of Ketamine Use Disorders: A Case Report and Literature Review (Verma, et al, 2025)
"findings consistent w/ 2 prior reports - use of naltrexone in KUDs at the dosage of 50 mg/day successfully helped patients achieve abstinence... naltrexone reduces antidepressant effects of ketamine, indicating overlap between opioid system & ketamine's NMDA receptor activity. "
Spotlight: Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring (in mice)
"we show that both parous parents and their children may be uniquely vulnerable to psychedelic treatment during the postpartum period"
Spotlight: Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study (Beaglehole, et al, 2025)
"We provide preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD."
Spotlight: The transformational power of psychedelics: catalysts for creativity, consciousness, and mental health (Du, et al, 2025)
"Psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), ketamine, and N,N-dimethyltryptamine (DMT), have captured the attention of scientists, artists, and seekers alike for their profound ability to alter consciousness and inspire creativity."
Zofia Kachlik